Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ai Lan Kobayashi

Pediatrics Papillion, NE Medical Doctor

NPI 1801097365 CMS profile 217893

401 E Gold Coast Rd, Suite 325, Papillion, NE 68046

Open in the dashboard

General payments

$28,482

84 records reported · program years 2019–2024

Research payments

$2,400

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ai Lan Kobayashi of Papillion, NE is reported in the CMS Open Payments database as having received $28,482 across 84 general payments and $2,400 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $150 1
2023 General $566 7
2022 General $12,083 20
2021 General $7,395 18
2020 General $254 3
2019 General $8,035 35
2019 Research $2,400 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ai Lan Kobayashi
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ai Lan Kobayashi were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ai Lan Kobayashi Pediatrics median Middle half National median
2019 $8,035 $86 $31–$183 $163
2020 $254 $49 $22–$110 $114
2021 $7,395 $68 $27–$158 $132
2022 $12,083 $77 $30–$173 $149
2023 $566 $88 $33–$190 $160
2024 $150 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Octapharma USA, Inc. $26,935 63 payments
  2. CSL Behring $276 5 payments
  3. Grifols Shared Services North America, Inc. $242 3 payments
  4. Genentech, Inc. $212 2 payments
  5. Grifols USA, LLC $208 2 payments
  6. Horizon Therapeutics plc $125 1 payment
  7. VYNE Pharmaceuticals Inc. $125 1 payment
  8. Pfizer Inc. $119 2 payments
  9. Sanofi Pasteur Inc. $119 2 payments
  10. Hospira, Inc. $65 1 payment
  11. Other $58 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $15,770 27 payments
  2. Honoraria $9,500 2 payments
  3. Food and Beverage $3,212 55 payments
Products named General payments · program years 2019–2024
  1. OCTAGAM IMMUNE GLOBULIN (HUMAN) $13,819 31 payments
  2. CUTAQUIG $13,181 33 payments
  3. Xembify $376 4 payments
  4. Hizentra $235 4 payments
  5. Xofluza $229 3 payments
  6. ACTIMMUNE $125 1 payment
  7. AMZEEQ $125 1 payment
  8. Gamunex-C $74 1 payment
  9. PANZYGA $65 1 payment
  10. OCTAGAM $65 1 payment
  11. Other $265 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Octapharma USA, Inc. $2,400 2 payments

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record